| Medical Policy |
| Subject: Surgical and Ablative Treatments for Chronic Headaches | |
| Document #: SURG.00096 | Publish Date: 11/19/2026 |
| Status: Revised | Last Review Date: 11/05/2026 |
| Description/Scope |
This document addresses surgical and ablative treatments for chronic headaches, such as migraine and tension type headaches, and occipital neuralgia. A variety of procedures are proposed for this purpose and include, for example, identification of nerve trigger points in the forehead and surgically removing muscle tissue from these areas. This document does not address nasal or sinus surgery.
Note: Please see the following related documents for additional information:
Note: For a high-level overview of this document, please see “Summary for Members and Families” below.
| Position Statement |
Investigational and Not Medically Necessary:
Surgical treatment for chronic headaches (including but not limited to chronic migraine headache and chronic tension type headache) is considered investigational and not medically necessary. This includes, but is not limited to, the following procedures:
Surgical and ablative treatments of occipital neuralgia are considered investigational and not medically necessary. This includes, but is not limited to, the following procedures for treatment of occipital neuralgia:
| Summary for Members and Families |
This document describes clinical studies and expert recommendations, and explains why surgery for chronic headaches and surgery or treatments that destroy nerve tissue for occipital neuralgia are not considered clinically appropriate. The following summary does not replace the medical necessity criteria or other information in this document. The summary may not contain all of the relevant criteria or information. This summary is not medical advice. Please check with your healthcare provider for any advice about your health.
Key Information
Many people get headaches that keep coming back. Migraines are one type. They can cause pain that lasts for hours or days. People with migraines may also feel sick to their stomach or bothered by bright lights and loud sounds. Most people take medicine to help with these headaches.
Some doctors have tried surgery to treat headaches that do not get better with medicine. In these surgeries, doctors remove small muscles in the forehead or back of the head. They think these muscles might be pressing on nerves and causing pain. Other surgeries involve cutting certain nerves.
A rare cause of headaches is a condition called occipital neuralgia. This causes sharp pain in the back of the scalp. Doctors have tried different procedures for this too. These include using heat or cold to destroy nerve tissue or surgery to take pressure off the nerves.
What the Studies Show
Some studies have found that surgery and treatments using radiofrequency energy may reduce headache pain. However, many studies do not compare the procedures with other treatments, or do not follow people long enough to know how well the benefits last. Studies of pulsed radiofrequency treatment have shown improvements in some people, but questions remain about its long-term benefits and how it compares with other treatments.
Is This Clinically Appropriate?
The available research has not established that these procedures provide benefits comparable to established treatments. Surgery for chronic headaches and surgery or treatments that destroy nerve tissue for occipital neuralgia are not considered clinically appropriate.
Because of this, the following procedures are not considered to be clinically appropriate:
The usual treatment for long-lasting headaches is still medicine.
| Rationale |
Summary
The evidence base for surgical and ablative interventions for chronic headache syndromes and occipital neuralgia is characterized by heterogeneous techniques, inconsistent diagnostic definitions, and limited use of blinded, controlled designs, constraining the ability to determine durable net health benefit. For migraine-related trigger site procedures, randomized controlled trials suggest potential symptom improvement in selected participants; however, interpretation is limited by uncertainty about participant selection, variable and sometimes non-validated outcome definitions, incomplete characterization of concurrent medical therapy, and analytic approaches such as multiple unadjusted comparisons that increase the risk of chance findings. Two randomized trials of pulsed radiofrequency (PRF) in chronic migraine reported fewer headache days or lower pain scores at 6 months compared with sham treatment or repeated nerve blocks, with no follow-up beyond 6 months. For occipital neuralgia, published studies of nerve decompression, neurolysis, neurectomy, and radiofrequency-based procedures most commonly relied on uncontrolled observational designs. Although improvements in pain intensity and frequency are frequently reported, the absence of sham-controlled or conservative-care comparators precludes confident attribution of benefit and does not allow comparative effectiveness assessment across modalities.
Discussion
Evidence quality
Across headache surgery, occipital nerve decompression, and radiofrequency techniques, the evidence base is largely derived from uncontrolled case series conducted in specialized centers. This study design increases susceptibility to referral bias, regression to the mean, placebo effects, and confounding from concurrent treatments that are not consistently described. As a result, findings have limited generalizability to routine community practice. Outcomes are predominantly participant-reported, use heterogenous and sometimes nonvalidated definitions, and are supported by incomplete or variable follow-up. These limitations are particularly consequential for procedures intended to produce irreversible anatomic change, where clinically meaningful benefit must be distinguished from short-term symptomatic fluctuation and where adverse effects may emerge late or be under-ascertained.
Professional Organization Positions
Professional positions underscore uncertainty about appropriate evidentiary thresholds rather than resolving it.
The American Society of Plastic Surgeons (ASPS) supports peripheral nerve or trigger site surgery for selected individuals with refractory chronic migraine based largely on early trial evidence and specialty-specific clinical experience, while still relying on a small and methodologically debated randomized evidence base (ASPS, 2018; Guyuron, 2005).
An American Society of Pain and Neuroscience (ASPN) guideline supports selective consideration of radiofrequency neurotomy for occipital neuralgia after diagnostic blockade and use of formal diagnostic criteria, while explicitly acknowledging heterogeneity in techniques and outcomes and the resulting difficulty synthesizing evidence quantitatively (Lee, 2021). The recommendation is graded II-2 C.
Collectively, these positions suggest that professional society recommendations are typically contingent on stringent participant selection and diagnostic confirmation yet are not supported by a robust body of comparative trial evidence.
Surgical and Radiofrequency Procedures for Migraine and Chronic Headache
Randomized trials evaluating trigger site deactivation and related peripheral nerve procedures contain findings consistent with symptom improvement in subsets of participants, but the internal validity of those findings is limited by study design and measurement issues.
The earliest randomized trial reported high rates of improvement and some headache elimination after surgery, with much lower improvement in controls, but incomplete characterization of placebo injection sites and responses, and limited reporting of concomitant migraine therapies, complicate interpretation (Guyuron, 2005).
A subsequent blinded, sham-controlled trial incorporated surgical exposure without resection in the sham arm. This strengthened inference relative to uncontrolled series, but evaluated numerous outcomes without clear prespecification and without adjustment for multiplicity, leaving uncertainty regarding which statistically significant findings represent reproducible treatment effects (Guyuron, 2009).
Longer-term observational follow-up suggests that improvement may persist in a proportion of operated participants, but these data are difficult to interpret without concurrent control groups and without standardized accounting for additional procedures during follow-up. Five-year follow-up of the initial trial cohort reported sustained improvement in most participants and complete headache elimination in a minority, but excluded those receiving additional trigger site procedures and did not provide comparable long-term control data (Guyuron, 2011).
A subsequent randomized study compared two surgical trigger-site deactivation techniques (nerve avulsion versus decompression), rather than surgery versus continued medical management or sham intervention, and therefore does not inform comparative effectiveness analysis regarding whether surgical treatment improves outcomes beyond non-surgical care (Guyuron, 2015).
Even when comparative designs were introduced, they often compared technical approaches rather than establishing efficacy relative to sham procedures or continued nonsurgical care. For example, a randomized trial in individuals with combined migraine and cervicogenic headache comparing proximal conventional radiofrequency to distal conventional radiofrequency reported superior outcomes with one approach, but this study design does not address whether radiofrequency ablation offers net benefit compared with nonablative management (AboElfadl, 2025). The mixed population limits application to isolated migraine or occipital neuralgia.
A small, randomized study comparing peripheral neurectomy with medical therapy reported statistically significant improvements in pain intensity, headache burden, and disability scores at 6 months in the surgical arm. However, the study enrolled only 26 participants (13 per group), relied exclusively on subjective outcome measures (visual analog score [VAS], migraine headache index [MHI], migraine disability assessment test [MIDAS], pain self-efficacy questionnaire [PSEQ]), and did not describe participant or assessor blinding. In addition, eligibility required a positive response to diagnostic local anesthetic blocks and treatment allocation was influenced by willingness to undergo surgery, introducing substantial selection and expectation bias. The short duration of follow-up further limits conclusions regarding durability of benefit for an irreversible intervention, particularly for outcomes known to be highly placebo- and expectation-sensitive (Bajaj, 2021).
Additional observational studies suggest reduced prescription medication days after surgery among survey responders, including reductions among participants reporting preoperative opioid use, but the lack of a non-surgical comparator and incomplete follow-up limit causal inference and may overestimate benefit if non-responders had poorer outcomes (Ortiz, 2021).
Secondary syntheses reach similar conclusions: a meta-analysis pooling a small number of randomized trials found higher odds of migraine elimination at 1 year in surgical groups but with wide confidence intervals and dependence on the limitations of the underlying trials, while other reviews highlight persistent problems with participant selection, sham control use, and outcome validity (Mathew, 2014; Vincent, 2019).
Pulsed Radiofrequency Therapy
PRF is a minimally invasive procedure involving percutaneous placement of an electrode to deliver radiofrequency energy to a targeted nerve. Unlike conventional thermal radiofrequency ablation, PRF is intended to modulate nerve signaling without producing destructive thermal lesions. Although the mechanisms and potential tissue effects differ, both procedures involve the application of physical energy to alter nerve function.
Cohen and colleagues (2015) conducted a multicenter, randomized, double-blind trial comparing PRF with corticosteroid injections and sham PRF in 81 individuals with occipital neuralgia or migraine with occipital nerve tenderness. At 6 weeks, PRF resulted in a greater reduction in average occipital pain compared with corticosteroid injections (mean change from baseline, -2.743 vs. -1.377; p=0.008), with a smaller difference persisting through 6 months. However, in the subgroup of 36 individuals with occipital neuralgia without migraine, there was no statistically significant difference in pain reduction between groups. The study was not powered for subgroup comparisons. There were also no significant between-group differences in headache frequency, headache-related disability, rescue medication use, or most other secondary outcomes. The authors concluded that PRF provided greater pain relief than corticosteroid injections, although this benefit was not consistently accompanied by improvement in other clinical outcomes.
De Oliveira and colleagues (2024) conducted a systematic review of 22 studies involving 608 individuals, including 2 randomized controlled trials, 11 cohort studies, and 9 case reports or series. The authors reported analgesic benefit lasting approximately 3 to 6 months for chronic migraine and 6 to 10 months for occipital neuralgia. However, most studies were observational, and substantial heterogeneity in headache diagnoses, treatment techniques, and outcome measures limited comparisons. The authors rated the quality of the evidence as “low.”
Two subsequent randomized trials evaluated PRF for chronic migraine. Tanyel Saraçoğlu and colleagues (2024) randomized 35 individuals to greater occipital nerve block combined with PRF or sham PRF, with 32 included in the analysis. At 6 months, mean monthly headache days were 3.44 with PRF and 16.00 with sham treatment (p<0.001). However, the trial was registered retrospectively, and did not assess disability or quality of life. Ertilav and Aydın (2024) randomized 70 individuals to PRF or 4 weekly greater occipital nerve blocks, with 67 included in the analysis. At 6 months, mean pain scores favored PRF (3.2 vs. 4.0; p=0.009). Migraine-related disability also favored PRF at 6 months (p<0.001). Participants were not blinded, and baseline differences between groups limited interpretation.
Dadali and colleagues (2025) conducted a prospective observational comparison involving 68 individuals with migraine, including 35 treated with greater occipital nerve PRF and 33 treated with repeated greater occipital nerve blocks. At 3 months, median monthly headache days were 4 with PRF and 14 with repeated blocks (p<0.001). The nonrandomized, single-center design, absence of a sham comparator, and follow-up limited to 3 months restricted conclusions regarding comparative effectiveness and durability.
Dadali and colleagues (2026) randomized 187 individuals with migraine to bilateral or unilateral proximal greater occipital nerve PRF. The 6-month per-protocol analysis included 166 individuals. Median monthly headache days were 7.0 with bilateral treatment and 10.0 with unilateral treatment (p=0.030). The absence of a sham comparator, lack of blinding, baseline differences, and exclusion of individuals who did not complete follow-up limited interpretation.
In a prospective, open-label, single-center study without a comparison group, Batistaki and colleagues (2021) performed PRF of the occipital nerves after a positive diagnostic nerve block in 57 individuals with chronic migraine (n=38), cluster headache (n=9), or tension type headache or occipital neuralgia (n=10). Among individuals with migraine, median headache episodes per month decreased from 14.5 at baseline to 4 at 1 month and 6.5 at 6 months (p=0.0001 for both). Reductions in the cluster headache group and the combined tension type headache and occipital neuralgia group were not statistically significant at 6 months, and the subgroup sizes of 9 and 10 individuals limited conclusions.
Randomized trials have demonstrated improvements in pain intensity or headache frequency following nonablative PRF compared with selected injection-based treatments in individuals with chronic migraine or migraine with occipital nerve tenderness. However, the trials use heterogeneous treatment protocols and comparators, and have not consistently demonstrated improvements in functional outcomes. Although these findings support a clinically meaningful treatment effect in selected populations, uncertainty remains regarding reproducibility, durability, and comparative effectiveness relative to established preventive therapies.
Occipital Neuralgia
For treatment of occipital neuralgia, studies evaluating nerve decompression and neurolysis or neurectomy frequently report substantial improvements in pain frequency, intensity, and medication use, but these findings arise primarily from uncontrolled case series and retrospective cohorts that cannot distinguish procedure effect from natural history, co-interventions, and measurement bias.
Across surgical decompression and ablative approaches (including neurolysis and radiofrequency-based techniques), the published evidence consists primarily of small, retrospective case series reporting that many treated individuals achieve ≥ 50% pain reduction and reductions in Numeric Rating Scale scores, with relatively low rates of major neurologic complications. However, these findings are derived from uncontrolled designs, heterogeneous diagnostic inclusion (often mixing occipital neuralgia with other chronic headache phenotypes), variable outcome definitions, and selective recruitment from specialized centers. Although randomized evidence is available for nonablative PRF, the evidence for surgical decompression and destructive ablative procedures remains predominantly uncontrolled. The absence of adequate comparative studies for these interventions, together with heterogeneous populations, variable outcome definitions, and substantial risks of selection and reporting bias, limits reliable assessment of their comparative effectiveness and durability.
Collectively, the evidence is insufficient to establish the net clinical benefit of decompression or ablative surgical interventions for occipital neuralgia or chronic headache syndromes (Austen, 2023; Pietramaggiori, 2023; Son, 2022).
Studies of defined subgroups such as iatrogenic occipital nerve injury similarly report marked improvements on multiple pain measures after mixed operative strategies, but referral and selection effects are likely, and the absence of non-operative comparators prevents estimation of incremental benefit attributable to surgery (Remy, 2024).
Nguyen and colleagues (2025) conducted a systematic review and meta-analysis of 12 studies involving 838 individuals undergoing occipital nerve decompression for occipital neuralgia. The pooled reduction in pain frequency was 20.30 days per month (95% confidence interval [CI], 16.53 to 24.08; p<0.0001). However, the included studies were predominantly observational, with substantial heterogeneity in participant selection, surgical techniques, and outcome assessment (I²=97.21%). The pooled results primarily reflect improvements from baseline rather than comparative effectiveness relative to nonsurgical treatment. A subsequent retrospective study of 53 individuals undergoing greater occipital nerve combing and decompression reported at least 50% improvement in occipital pain in 47 of 53 individuals after a minimum of 12 months of follow-up (Zhang, 2026). Although these findings suggest that selected individuals may experience substantial improvement following surgery, the absence of adequate controls limits conclusions regarding the incremental benefit and durability of surgical decompression compared with established alternatives.
Longer follow-up describing reoperation rates adds clinically relevant safety and durability information, and identifies factors such as prior radiofrequency ablation and cervical spine disorders as predictors of reoperation, but does not establish that decompression improves outcomes relative to conservative management or clarify optimal sequencing of interventions (Remy, 2025). In a retrospective cohort of 81 individuals treated with ultrasound-guided hydrodissection combined with radiofrequency-assisted fascial release, median symptom relief lasted 6 months during a mean follow-up of 12.39 months, and 30 individuals underwent repeat intervention (Yao, 2026). The absence of a comparison group prevented assessment of the separate contributions of hydrodissection and radiofrequency-assisted fascial release.
Neurolysis and neurectomy series likewise report high rates of pain relief, including complete relief in substantial minorities, but are limited by lack of controls and often rely on center-specific selection and outcome assessment (Ducic, 2009; Gille, 2004).
In defined postoperative populations such as individuals developing occipital neuralgia after acoustic neuroma resection, mixed procedural approaches alongside conservative management produced pain relief in many participants, but small numbers and heterogeneity of treatments preclude conclusions about which intervention is effective and for whom (Riedy, 2022).
Unlike nonablative PRF, conventional thermal radiofrequency ablation produces tissue lesions intended to interrupt nerve signaling. Observational studies have reported reductions in pain intensity and headache frequency following thermal ablation for refractory occipital neuralgia. However, these studies generally lack sham or active comparators and provide limited information regarding long-term effectiveness, repeat procedures, and sensory complications. Findings from randomized trials of nonablative PRF cannot be directly extrapolated to destructive thermal ablation.
Radiofrequency-based treatments demonstrate a consistent pattern across the available literature: retrospective single-center cohorts of thermal radiofrequency ablation report mean reductions in pain scores and relief lasting several months after select procedures. However, these findings derive from uncontrolled designs with heterogeneous headache phenotypes, variable nerve targets, and nonstandardized outcome definitions, often following positive diagnostic blocks that enrich for responders. Larger datasets increase procedural counts but do not address core threats to validity, including absence of concurrent comparators, inconsistent follow-up intervals, reliance on subjective pain measures, and limited accounting for repeat procedures or co-interventions. Adverse events are reported as uncommon and generally transient, but safety conclusions are constrained by retrospective ascertainment and short, nonuniform surveillance. Collectively, these features preclude reliable estimation of treatment effect size or durability and limit generalizability beyond specialized centers (Abd-Elsayed, 2026; Hoffman, 2018). In a retrospective cohort of 18 individuals with refractory occipital neuralgia, 66% reported at least 50% pain reduction 12 months after ultrasound-guided proximal greater occipital nerve radiofrequency ablation, without a comparison group (Turan, 2025). At 12 months, 7 of 18 individuals (38.9%) met the study-defined success threshold of a Numeric Rating Scale score below 4, a distinct end point from at least 50% pain reduction.
Integrated Interpretation Across Conditions and Procedures
The evidence supporting surgical and radiofrequency procedures for chronic headaches and occipital neuralgia varies by intervention. Randomized trials of nonablative PRF have demonstrated improvements in pain outcomes compared with selected injection-based treatments, particularly in individuals with chronic migraine or migraine with occipital nerve tenderness. However, these studies have not consistently demonstrated improvements in functional outcomes, and uncertainty remains regarding reproducibility, durability, and comparative effectiveness relative to established preventive treatments.
Studies of occipital nerve decompression, neurolysis, neurectomy, and destructive radiofrequency ablation frequently report substantial improvement following treatment. However, these findings arise predominantly from uncontrolled observational studies with heterogeneous populations, variable selection criteria, and limited comparative evidence.
Although selected professional societies recognize these procedures for refractory headache disorders or occipital neuralgia, their recommendations differ in scope and evidentiary support. Overall, the available evidence does not establish that these interventions consistently provide clinically effective and durable therapeutic results at least equivalent to appropriate established alternatives.
| Background/Overview |
According to the International Headache Society (IHS), primary headaches are those that are not associated with any demonstrable organic disease, structural or neurologic abnormality. Two types of primary headache are tension type headache (also known as ordinary headache, stress headache and idiopathic headache) and migraine. Chronic headache, whether migraine or non-migraine, is defined as occurring on 15 or more days per month for more than 3 months, with migraine features or migraine-specific treatment response on at least 8 of those days for chronic migraine.
Tension type headaches are very common; estimates of lifetime prevalence range from 30% to 78% of the population (IHS, 2018). Migraine affects approximately 12% of people in the United States (U.S. National Library of Medicine, 2025). The exact pathology of migraines is unknown, but it is felt that a family history of migraine headaches, medications (for example, birth control pills, vasodilators), fatigue, emotional stress and specific foods or alcohol are probable triggers. Migraines manifest as a recurring attack usually lasting for 4-72 hours and involving pain of moderate to severe intensity, often with nausea, sometimes vomiting, sensitivity to light, sound and other sensory stimuli. Management of headaches has consisted largely of pharmacologic treatment (IHS, 2018).
Migraines are generally treated by two approaches: abortive and preventive. The goal of abortive therapy is to prevent a migraine attack or to stop it once it starts. Medications are prescribed to stop a headache during its prodrome stage or once it has begun and may be taken as needed. Preventive treatment is considered if an individual has more than one migraine per week. The goal is to lessen the frequency and severity of the migraine attacks with daily medication.
It has been proposed that activation of peripheral sensory nerves, including the trigeminal nerve, causes release of peptides, (for example, substance P, calcitonin gene-related peptide, neurokinins), resulting in vasodilatation and migraine headache. Also suggested is that trigger points can be identified, particularly in the region of the forehead, at which peripheral nerve activation occurs.
Occipital neuralgia is classified in the International Classification of Headache Disorders, 3rd edition, within painful lesions of the cranial nerves and other facial pain (IHS, 2018). In this case, accurate diagnosing is important because occipital neuralgia must be distinguished from referred pain arising from upper cervical joints or tender muscle trigger points.
| Definitions |
Aura: Symptoms such as disturbances in vision, smell or perception that occur prior to a migraine that serve as a warning that the headache may follow.
Etiology: The cause or origin of disease.
Hydrodissection: Injection of fluid to separate a nerve from surrounding tissue or adhesions (Yao, 2026).
Neuralgia: An intense burning or stabbing pain caused by irritation or nerve damage from systemic disease, inflammation, infection, and compression or physical irritation of a nerve.
Neurolysis: Destruction of nerve tissue; freeing of a nerve from inflammatory adhesions (American Association of Neurological Surgeons, n.d.; Gupta, 2025).
Neuroplasty: Surgery to repair or restore nerve tissue.
Nociceptive: Relating to the detection and neural processing of stimuli that damage or threaten to damage tissue (International Association for the Study of Pain, n.d.).
Occipital: Relating to the back of the head or skull.
Prodrome: The period of time preceding a migraine headache during which a person may feel irritable, out of sorts, moody, unusually sensitive to light or noise, and may notice some fluid retention; this may go on for 1 or 2 days or just a few hours before the actual headache begins.
Pulsed radiofrequency: Delivery of intermittent radiofrequency energy intended to alter nerve signaling while limiting tissue heating, rather than producing the thermal lesion used in conventional radiofrequency ablation (Lee, 2021).
Trigger point: Hyperirritable spots in skeletal muscle that are associated with palpable nodules in taut bands of muscle fibers; the palpable nodules are said to be small contraction knots and a common cause of pain. Compression of a trigger point may elicit local tenderness, referred pain, or motor dysfunction.
| Coding |
The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
When services are Investigational and Not Medically Necessary:
For the following procedure codes for the headache diagnoses listed, or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.
| CPT |
|
| 14040-14041 |
Adjacent tissue transfer or rearrangement, forehead, cheeks chin, mouth, neck, axillae, genitalia, hands and/or feet |
| 14060-14061 |
Adjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips |
| 15824 |
Rhytidectomy; forehead |
| 15826 |
Rhytidectomy; glabellar frown lines |
| 64640 |
Destruction by neurolytic agent; other peripheral nerve or branch [when specified as thermal or cryodenervation of occipital nerve] |
| 64716 |
Neuroplasty and/or transposition, cranial nerve |
| 64722 |
Decompression; unspecified nerve(s) [for example, occipital nerve] |
| 64732 |
Transection or avulsion of; supraorbital nerve |
| 64734 |
Transection or avulsion of; infraorbital nerve |
| 64744 |
Transection or avulsion of; greater occipital nerve |
| 64771 |
Transection or avulsion of other cranial nerve, extradural |
| 64772 |
Transection or avulsion of other spinal nerve, extradural |
| 64787 |
Implantation of nerve end into bone or muscle |
| 64999 |
Unlisted procedure, nervous system [when specified as pulsed radiofrequency treatment] |
| 67900 |
Repair of brow ptosis (supraciliary, mid-forehead or coronal approach) |
|
|
|
| ICD-10 Procedure |
|
| 00BK0ZZ-00BK4ZZ |
Excision of trigeminal nerve [by approach; includes codes 00BK0ZZ, 00BK3ZZ, 00BK4ZZ] |
| 01510ZZ-01514ZZ |
Destruction of cervical nerve [by approach; includes codes 01510ZZ, 01513ZZ, 01514ZZ] |
| 01810ZZ-01814ZZ |
Division of cervical nerve [by approach; includes codes 01810ZZ, 01813ZZ, 01814ZZ] |
| 01N10ZZ-01N14ZZ |
Release cervical nerve [by approach; includes codes 01N10ZZ, 01N13ZZ, 01N14ZZ] |
| 0J010ZZ-0J013ZZ |
Alteration of face subcutaneous tissue and fascia [by approach; includes codes 0J010ZZ, 0J013ZZ] |
| 0KB00ZZ-0KB04ZZ |
Excision of head muscle [by approach; includes codes 0KB00ZZ, 0KB03ZZ, 0KB04ZZ] |
| 0KB10ZZ-0KB14ZZ |
Excision of facial muscle [by approach; includes codes 0KB10ZZ, 0KB13ZZ, 0KB14ZZ] |
|
|
|
| ICD-10 Diagnosis |
|
| G43.001-G43.E19 |
Migraine |
| G44.001-G44.099 |
Cluster headaches and other trigeminal autonomic cephalgias (TAC) |
| G44.201-G44.229 |
Tension-type headache |
| G50.1 |
Atypical facial pain |
| M54.81 |
Occipital neuralgia |
| R51.0-R51.9 |
Headache |
| References |
Peer Reviewed Publications:
Government Agency, Medical Society, and Other Authoritative Publications:
| Websites for Additional Information |
| Index |
Aura
Cephalalgia
Headache, Migraine
Migraine
Neuralgia
Neurolysis
Neuroplasty
Occipital
Pulsed Radiofrequency
Radiofrequency Ablation
| Document History |
| Status |
Date |
Action |
| Revised |
11/05/2026 |
Medical Policy & Technology Assessment Committee (MPTAC) review. Revised INV and NMN statement to remove closure of patent foramen ovale. Revised Description/Scope, Summary for Members and Families, Rationale, Background/Overview, Definitions, References, and Websites for Additional Information sections. Revised Coding section, removed codes 93580, 02U53JZ, 02U54JZ. |
| Reviewed |
02/19/2026 |
MPTAC review. Added “Summary for Members and Families” section. Revised Description/Scope, Rationale, Background/Overview, References, Websites for Additional Information and Index sections. |
| Reviewed |
02/20/2025 |
MPTAC review. Revised Rationale and References sections. |
| Reviewed |
02/15/2024 |
MPTAC review. Rationale and References sections updated. |
|
|
09/27/2023 |
Updated Coding section with 10/01/2023 ICD-10-CM changes; added G43.E19 to end of range. |
| Reviewed |
02/16/2023 |
MPTAC review. Rationale and References sections updated. |
| Revised |
02/17/2022 |
MPTAC review. Removed bullet point on nasal and sinus surgery from INV&NMN statement. Rationale and References sections updated. Updated Coding section to remove nasal and sinus procedure CPT codes 30130, 30140, 30520, 31200, 31201, 31205, 31254, 31255 and associated ICD-10-PCS codes no longer addressed. |
| Reviewed |
02/11/2021 |
MPTAC review. Rationale and References sections updated. |
|
|
10/01/2020 |
Updated Coding section with 10/01/2020 ICD-10-CM changes; added R51.0-R51.9 replacing R51 deleted 09/30/2020. |
| Reviewed |
02/20/2020 |
MPTAC review. Rationale and References sections updated. Updated Coding section; added CPT 14040, 14041, 14060, 14061, 64716, 64771, 64772, 64787; expanded diagnosis range. |
| Reviewed |
03/21/2019 |
MPTAC review. Rationale and References sections updated. |
| Reviewed |
03/22/2018 |
MPTAC review. The document header wording updated from “Current Effective Date” to “Publish Date.” Rationale, Background/Overview and References sections updated. |
| Reviewed |
05/04/2017 |
MPTAC review. Updated the formatting in the Position Statement section. The References section was updated. |
| Reviewed |
05/05/2016 |
MPTAC review. Rationale and Reference sections updated. Removed ICD-9 codes from Coding section. |
| Reviewed |
05/07/2015 |
MPTAC review. Description, Rationale and References sections updated. |
| Reviewed |
05/15/2014 |
MPTAC review. Description, Rationale, Coding and References sections updated. |
| Reviewed |
05/09/2013 |
MPTAC review. Rationale, References and Index sections updated. |
| Reviewed |
05/10/2012 |
MPTAC review. No change to position statement. Rationale updated to address nasal contact point. |
| Revised |
02/16/2012 |
MPTAC review. Title changed. Position statement revised to clarify nasal surgery criteria and the inclusion of surgical/ablative treatments of occipital neuralgia as investigational and not medically necessary. Description, Rationale, Background, Definitions, Coding and References updated. |
| Reviewed |
02/17/2011 |
MPTAC review. Rationale and References updated. |
| Reviewed |
02/25/2010 |
MPTAC review. Rationale and References updated. |
| Reviewed |
02/26/2009 |
MPTAC review. References updated. |
|
|
10/01/2008 |
Updated Coding section with 10/01/2008 ICD-9 changes. |
| Reviewed |
02/21/2008 |
MPTAC review. References updated. The phrase “investigational/not medically necessary” was clarified to read “investigational and not medically necessary.” This change was approved at the November 29, 2007 MPTAC meeting. |
| New |
03/08/2007 |
MPTAC review. Initial document development. |
Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.
No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.
© CPT Only – American Medical Association